Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of tigecycline in the treatment of subjects with selected
serious infections caused by resistant gram-negative bacteria, eg, Acinetobacter baumannii,
Enterobacter species, Klebsiella pneumoniae or other resistant gram-negative pathogens, for
whom antibiotics have failed or who cannot tolerate other appropriate antimicrobial
therapies. The primary efficacy endpoint will be the clinical response.